HMOX1 emerges as a novel therapeutic target in CLL, and the use of HMOX1 modulators in conjunction with arsenic trioxide might be an effective treatment approach in CLL [218]. Here, HMOX1 is linked to B-cell chronic lymphocytic leukemia.